A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours-Reference-Cited by-同舟云学术

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

Published:2017-05 Issue: Volume:76 Page:144-151
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

de Jonge Maja,de Weger Vincent A.,Dickson Mark A.,Langenberg Marlies,Le Cesne Axel,Wagner Andrew J.,Hsu Karl,Zheng Wei,Macé Sandrine,Tuffal Gilles,Thomas Koruth,Schellens Jan H.M.

Funder

Sanofi

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference19 articles.

1. TP53 mutations in human cancers: origins, consequences, and clinical use;Olivier;Cold Spring Harb Perspect Biol,2010

2. The p53-mdm-2 autoregulatory feedback loop;Wu;Genes Dev,1993

3. MDM2 is a central node in the p53 pathway: 12 years and counting;Bond;Curr Cancer Drug Targets,2005

4. MDM2–master regulator of the p53 tumor suppressor protein;Momand;Gene,2000

5. p53 mutation and MDM2 amplification in human soft tissue sarcomas;Leach;Cancer Res,1993

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular characteristics and systemic treatment options of liposarcoma: A systematic review;Biomedicine & Pharmacotherapy;2024-09

2. A first-in-human phase I study of a novel MDM2/p53 inhibitor alrizomadlin in advanced solid tumors;ESMO Open;2024-08

3. Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches;Molecular Cancer;2024-07-25

4. Targeting Hdm2 and Hdm4 in Anticancer Drug Discovery: Implications for Checkpoint Inhibitor Immunotherapy;Cells;2024-06-29

5. E3 ligases and DUBs target ferroptosis: A potential therapeutic strategy for neurodegenerative diseases;Biomedicine & Pharmacotherapy;2024-06